U.S. markets open in 4 hours 16 minutes
  • S&P Futures

    4,306.75
    -43.00 (-0.99%)
     
  • Dow Futures

    34,194.00
    -374.00 (-1.08%)
     
  • Nasdaq Futures

    14,647.25
    -155.00 (-1.05%)
     
  • Russell 2000 Futures

    2,215.50
    -33.30 (-1.48%)
     
  • Crude Oil

    71.12
    -1.08 (-1.50%)
     
  • Gold

    1,814.70
    +12.60 (+0.70%)
     
  • Silver

    26.26
    +0.14 (+0.52%)
     
  • EUR/USD

    1.1826
    +0.0027 (+0.22%)
     
  • 10-Yr Bond

    1.3210
    0.0000 (0.00%)
     
  • Vix

    18.96
    +2.52 (+15.33%)
     
  • GBP/USD

    1.3781
    -0.0017 (-0.12%)
     
  • USD/JPY

    109.9160
    -0.7140 (-0.65%)
     
  • BTC-USD

    32,495.59
    -2,266.75 (-6.52%)
     
  • CMC Crypto 200

    814.79
    -51.53 (-5.95%)
     
  • FTSE 100

    7,059.86
    -91.16 (-1.27%)
     
  • Nikkei 225

    28,118.03
    -248.92 (-0.88%)
     

Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026

·2 min read

Summary The Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026 gives a COVID-19 disease overview, epidemiology overview, current marketed vaccines, unmet needs, pipeline assessment, and market outlook.

New York, July 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026" - https://www.reportlinker.com/p06103610/?utm_source=GNW


The analyst forecast three different potential scenarios for the future use of COVID-19 vaccines -
- The first scenario assumes that annual vaccination with a COVID-19 vaccine will be needed.
- The second scenario assumes annual vaccination for the high-risk population of people 65 years of age and older, while everyone below 65 years of age will need a vaccine only every two years.
- In the third scenario, the high-risk population of people 65 years of age and older will receive a COVID-19 vaccine every two years, while everyone below 65 years will need a vaccine only every five years.

Scope
This report includes -
- Executive Summary
- Disease Overview: History of the outbreak, Etiology and Pathophysiology
- Epidemiology
- Current Vaccination Options: Includes detailed product profiles with SWOT analysis
- Unmet Need and Opportunities: Detailing the major unmet needs with significant KOL insights
- Pipeline Assessment: Includes pipeline overview and detailed product profiles with SWOT analysis
- R&D Strategies: Trends in Clinical Trial Design for COVID-19 Vaccines and Trends in Deal-Making
- Market Outlook

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM COVID-19 vaccine.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global COVID-19 vaccine market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06103610/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001